Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

Inclusion Criteria:

• Is of American Society of Anesthesiologists (ASA) 1 - 4;
• Is above or equal to the age of 18;
• Scheduled for surgical procedures with a general anesthesia with the use of rocuronium or vecuronium for endotracheal intubation and maintenance of neuromuscular block;
• Scheduled for surgical procedure in supine position;
• Given written informed consent.

Exclusion Criteria:

• Participants in whom a difficult intubation because of anatomical malformations was expected;
• Is known or suspected to have neuromuscular disorders impairing neuromuscular block (NMB) and/or significant renal dysfunction;
• Is known or suspected to have a (family) history of malignant hyperthermia;
• Is known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;
• Is receiving medication in a dose and/or at a time point known to interfere with neuromuscular blocking agents such as antibiotics, anticonvulsants and Mg2+;
• Participants in whom the use of neostigmine and/or glycopyrrolate may be contraindicated;
• Had already participated in a sugammadex trial;
• Had participated in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into P05960.
• Females who are pregnant:
• Females of childbearing potential not using any method of birth control: condom or using only hormonal contraception as birth control;
• Females who were breast-feeding.